Skip to main content
Premium Trial:

Request an Annual Quote

Reader Response: Ciphergen Responds to Lumicyte Story: ABI nixes Lite Brite

Premium

William Rich, CEO of Ciphergen, writes to BioArray News:

...The March 15 article “Lumicyte Battles Arch-Rival Ciphergen For Protein Profiling Biochip Dominance,” leaves readers with what I believe is a false impression — that because we sell our system in the research market, as well as perform services here, our ProteinChip technology has limited capability. Let me set the record straight.

The article states that Ciphergen’s ProteinChip Arrays are “basic” and can be used in “ordinary” labs. Our ProteinChip Systems and Arrays were intentionally designed to provide such ease-of-use that they can be used by the benchtop scientist. However, merely because our biochips are easy to use does not mean that they have inferior or lower level performance. Ciphergen’s ProteinChip Arrays incorporate advanced surface chemistries that result from our continuous research and development in SELDI (Surface Enhanced Laser Desorption/Ionization) technology. These biochips are routinely used in large-scale discovery and validation studies as part of collaborative services conducted through our Biomarker Centers...The article also states, “Ciphergen chips do not allow identification of proteins.” This is simply not true. Our customers routinely identify proteins captured on our ProteinChip Arrays using either our ProteinChip Systems or our ProteinChip tandem MS interface. Finally, your article implied that Ciphergen has not developed pattern recognition capability. In fact, Ciphergen’s ProteinChip Biomarker System, introduced in 2001, incorporates Biomarker Patterns software as an essential component. This software uses powerful clustering algorithms to identify patterns of biomarker expression that differentiate classes of biological samples.

 

Applied Biosystems has said that the SNP genotyping system mentioned in the March 22 BioArray News article, “Illumina Hopes to Sow the Beads of a Second Microarray Revolution,” is not going to be called Lite Brite: this is just an in-house project name. Second, ABI said it is supplying its Oligonucleotide Ligase Assay (OLA) to the genotyping system. The assay, which is highly multiplexed, will play a key role, along with Illumina’s arrays in enabling users of the system to do "ultra high-throughput SNP genotyping" at a cost far below what current systems offer, ABI said. The system will do 141,696 genotypes per plate and is slated for an August launch.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.